Displaying drugs 6701 - 6725 of 8297 in total
Methylmalonic Acid
A malonic acid derivative which is a vital intermediate in the metabolism of fat and protein. Abnormalities in methylmalonic acid metabolism lead to methylmalonic aciduria. This metabolic disease is attributed to a block in the enzymatic conversion of methylmalonyl CoA to succinyl CoA. [PubChem]
Experimental
Matched Description: … A malonic acid derivative which is a vital intermediate in the metabolism of fat and protein. ... This metabolic disease is attributed to a block in the enzymatic conversion of methylmalonyl CoA to succinyl …
Virginiamycin S1
One of the components of virginiamycin, a cyclic polypeptide antibiotic complex from streptomyces virginiae, s. Loidensis, s. Mitakaensis, s. Pristina-spiralis, s. Ostreogriseus, and others. It is used to treat infections with gram-positive organisms and as a growth promoter in cattle, swine, and poultry.
Experimental
Matched Description: … One of the components of virginiamycin, a cyclic polypeptide antibiotic complex from streptomyces virginiae …
Cediranib
The novel indole-ether quinazoline Cediranib is a highly potent (IC50 < 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro. It is being developed clinically as a once-daily oral therapy for the treatment of cancer.
Investigational
Matched Description: … It is being developed clinically as a once-daily oral therapy for the treatment of cancer. ... quinazoline Cediranib is a highly potent (IC50 < 1 nmol/L) ATP-competitive inhibitor of …
rhIGFBP-3
rhIGFBP-3 (recombinant human insulin-like growth factor binding protein-3) is Insmed’s proprietary anti-cancer compound that has demonstrated significant decreases in cancerous growth in several models of human. It is developed by Insmed and is currently under phase I of the clinical trial.
Investigational
Matched Description: … It is developed by Insmed and is currently under phase I of the clinical trial. ... anti-cancer compound that has demonstrated significant decreases in cancerous growth in several models of …
Vicriviroc
Vicriviroc, also known as SCH 417690 and SCH-D, is currently in clinical trials for the management of HIV-1. This pyrimidine based drug inhibits the interaction of HIV-1 with CCR5, preventing viral entry into cells. This drug was developed by Schering-Plough.
Investigational
Matched Description: … Vicriviroc, also known as SCH 417690 and SCH-D, is currently in clinical trials for the management of ... This pyrimidine based drug inhibits the interaction of HIV-1 with CCR5, preventing viral entry into cells …
Roxarsone
Roxarsone is an organoarsenic molecule added to poultry feed. The addition of this compound to poultry feed improves weight gain and feed efficiency as well as prevent the growth of coccidian parasites. The drug is also approved in the United States for use in pigs.
Vet approved
Matched Description: … the growth of coccidian parasites. ... The addition of this compound to poultry feed improves weight gain and feed efficiency as well as prevent …
Matrix-M
Matrix-M is a saponin-based adjuvant made of nanometer particles, cholesterol, and phospholipid that is developed by Novavax. This compound is administered alongside vaccines to enhance biological functions: creating robust and long-lasting immune responses that may allow for dose-sparing of vaccines.
Investigational
Matched Description: … Matrix-M is a saponin-based adjuvant made of nanometer particles, cholesterol, and phospholipid that ... biological functions: creating robust and long-lasting immune responses that may allow for dose-sparing of …
Pegsitacianine
Pegsitacianine is under investigation in clinical trial NCT05576974 (A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)).
Investigational
Matched Description: … NCT05576974 (A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of ... Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients …
ATL1102
ATL1102 is a second-generation antisense inhibitor of CD49d, an immunesystem protein known as VLA-4, an immune cell molecule. It works by entering cells and targeting genes.
Investigational
Matched Description: … ATL1102 is a second-generation antisense inhibitor of CD49d, an immunesystem protein known as VLA-4, …
Laromustine
VNP40101M is a novel alkylating agent that has been used in trials studying the treatment of Leukemia, Lymphoma, Lung Cancer, Small Intestine Cancer, and Myelodysplastic Syndromes, among others.
Investigational
Matched Description: … VNP40101M is a novel alkylating agent that has been used in trials studying the treatment of Leukemia …
Tandamine
Tandamine was researched in 1970s as an antidepressant but was never commercialized. Tandamine is an analog of pirandamine and it acts as a selective serotonin reuptake inhibitor (SSRI).
Experimental
Matched Description: … Tandamine is an analog of pirandamine and it acts as a selective serotonin reuptake inhibitor (SSRI). …
Eleclazine
Eleclazine has been used in trials studying the treatment of LQT2 Syndrome, Long QT Syndrome, Ischemic Heart Disease, Ventricular Arrhythmia, and Long QT Syndrome Type 3, among others.
Investigational
Matched Description: … Eleclazine has been used in trials studying the treatment of LQT2 Syndrome, Long QT Syndrome, Ischemic …
MIP-1095 I-123
123 I Mip 1095 is under investigation in clinical trial NCT00712829 (Study to Evaluate the Safety, Pharmacokinetics, Tissue Distribution, Metabolism and Dosimetry of Two Prostate Cancer Imaging Agents).
Investigational
Matched Description: … NCT00712829 (Study to Evaluate the Safety, Pharmacokinetics, Tissue Distribution, Metabolism and Dosimetry of …
Nerofe
Nerofe is under investigation in clinical trial NCT03059615 (A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS).
Investigational
Matched Description: … Nerofe is under investigation in clinical trial NCT03059615 (A Phase 2a, Open-Label, Two Stage Study of …
Tavapadon
Tavapadon is under investigation in clinical trial NCT02262767 (A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 Co-administered With Trimethobenzamide Hydrochloride in Healthy Subjects).
Investigational
Matched Description: … in clinical trial NCT02262767 (A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of …
PCS-499
PCS-499 is under investigation in clinical trial NCT01487109 (A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients).
Investigational
Matched Description: … under investigation in clinical trial NCT01487109 (A Phase 2 Study to Evaluate the Safety and Efficacy of …
Ontamalimab
Ontamalimab is under investigation in clinical trial NCT03627091 (Efficacy and Safety Study of SHP647 as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307)).
Investigational
Matched Description: … Ontamalimab is under investigation in clinical trial NCT03627091 (Efficacy and Safety Study of SHP647 …
Silmitasertib
Silmitasertib is under investigation in clinical trial NCT03904862 (Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery).
Investigational
Matched Description: … Silmitasertib is under investigation in clinical trial NCT03904862 (Testing the Safety and Tolerability of …
Zampilimab
Zampilimab is under investigation in clinical trial NCT04335578 (A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of UCB7858 in Adult Kidney Transplant Recipients With Chronic Allograft Injury).
Investigational
Matched Description: … clinical trial NCT04335578 (A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of …
Volagidemab
Volagidemab is under investigation in clinical trial NCT03117998 (Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus).
Investigational
Matched Description: … clinical trial NCT03117998 (Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of …
MaxAdFVIII
MaxAdFVIII is an adenoviral vector that expresses the full-length human Factor VIII (hFVIII) cDNA. First developed by GenStar, it is being investigated for the treatment of hemophilia.
Investigational
Matched Description: … First developed by GenStar, it is being investigated for the treatment of hemophilia. …
RLYB212
RLYB212 is a human monoclonal antibody against Antigen-1A Immunoglobulin (HPA-1A). It is currently being developed by Rallybio for the prevention of fetal and neonatal alloimmune thrombocytopenia.
Investigational
Matched Description: … It is currently being developed by Rallybio for the prevention of fetal and neonatal alloimmune thrombocytopenia …
Bacteroides thetaiotaomicron
Bacteroides thetaiotaomicron is a live biotherapeutic. Developed by 4D Pharma, Thetanix, an oral formulation comprising lyophilized Bacteroides thetaiotaomicron, is being investigated for the treatment of Crohn’s disease.
Investigational
Matched Description: … formulation comprising lyophilized Bacteroides thetaiotaomicron, is being investigated for the treatment of …
Ispectamab debotansine
Ispectamab debotansine is an antibody drug conjugate comprised of an anti-B cell maturation (BCMA) IgG1 humanized antibody conjugated covalently to the dibenzocyclooctyne (DBCO) noncleavable linker maytansinoid warhead.
Investigational
Matched Description: … Ispectamab debotansine is an antibody drug conjugate comprised of an anti-B cell maturation (BCMA) IgG1 …
LMB-100
LMB-100 is a is an antibody-toxin conjugate with an antimesothelin Fab linked to a 24-kilodalton portion of Pseudomonas exotoxin A with mutations that decrease immunogenicity.
Investigational
Matched Description: … 100 is a is an antibody-toxin conjugate with an antimesothelin Fab linked to a 24-kilodalton portion of …
Displaying drugs 6701 - 6725 of 8297 in total